{"id":"vehicle-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Application site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vehicle Foam serves as a delivery system or base formulation for topical medications. As a foam, it provides improved spreadability, cosmetic elegance, and potentially enhanced penetration compared to traditional creams or ointments. The specific active ingredient and mechanism depend on what therapeutic agent is incorporated into the foam vehicle.","oneSentence":"Vehicle Foam is a topical foam formulation designed to deliver active pharmaceutical ingredients to the skin surface for localized therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:15:07.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Topical dermatological conditions (specific indication dependent on active ingredient formulated in vehicle)"}]},"trialDetails":[{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":"Psoriasis Vulgaris, Psoriasis, Skin Diseases","enrollment":12},{"nctId":"NCT07184645","phase":"PHASE3","title":"A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"Atopic Dermatitis (AD)","enrollment":198},{"nctId":"NCT07173478","phase":"PHASE3","title":"A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2025-10","conditions":"Atopic Dermatitis (AD)","enrollment":156},{"nctId":"NCT05028582","phase":"PHASE3","title":"Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Scalp Psoriasis","enrollment":432},{"nctId":"NCT01866163","phase":"PHASE3","title":"LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-06","conditions":"Psoriasis Vulgaris","enrollment":426},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":"Psoriasis Vulgaris","enrollment":504},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":376},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":"Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT03442244","phase":"PHASE1","title":"Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-01-30","conditions":"Psoriasis Vulgaris","enrollment":20},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT04973228","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-07-08","conditions":"Seborrheic Dermatitis","enrollment":457},{"nctId":"NCT04960930","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris","status":"COMPLETED","sponsor":"Cutia Therapeutics (Shanghai) Co., Ltd","startDate":"2021-09-17","conditions":"Acne Vulgaris","enrollment":372},{"nctId":"NCT04091646","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-04","conditions":"Seborrheic Dermatitis","enrollment":226},{"nctId":"NCT01555463","phase":"PHASE3","title":"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-09","conditions":"Papulopustular Rosacea","enrollment":961},{"nctId":"NCT02094716","phase":"PHASE2","title":"A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-04","conditions":"Scabies","enrollment":130},{"nctId":"NCT04128007","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-01-13","conditions":"Plaque Psoriasis","enrollment":304},{"nctId":"NCT02815267","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":466},{"nctId":"NCT03271021","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-07-17","conditions":"Acne Vulgaris","enrollment":1488},{"nctId":"NCT02815280","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":495},{"nctId":"NCT01072877","phase":"PHASE3","title":"Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-12","conditions":"Varicose Veins","enrollment":279},{"nctId":"NCT01231373","phase":"PHASE3","title":"Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-11","conditions":"Varicose Veins","enrollment":235},{"nctId":"NCT01197833","phase":"PHASE3","title":"Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-09","conditions":"Great Saphenous Vein Incompetence, Visible Varicosities","enrollment":117},{"nctId":"NCT04104685","phase":"PHASE2","title":"A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2019-09-18","conditions":"Acne Vulgaris","enrollment":446},{"nctId":"NCT03142451","phase":"PHASE3","title":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-02","conditions":"Facial Papulopustular Rosacea","enrollment":751},{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Plaque Psoriasis, Psoriasis","enrollment":25},{"nctId":"NCT04608500","phase":"PHASE3","title":"A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-01","conditions":"Facial Papulopustular Rosacea","enrollment":771},{"nctId":"NCT04571151","phase":"PHASE4","title":"Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis","status":"UNKNOWN","sponsor":"Skin Sciences, PLLC","startDate":"2021-01","conditions":"Plaque Psoriasis","enrollment":30},{"nctId":"NCT03848871","phase":"PHASE4","title":"The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2017-12-12","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT02899962","phase":"PHASE3","title":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-02-15","conditions":"Psoriasis Vulgaris","enrollment":722},{"nctId":"NCT02267746","phase":"PHASE3","title":"A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2014-06","conditions":"Acne Vulgaris","enrollment":893},{"nctId":"NCT02654769","phase":"PHASE3","title":"A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":441},{"nctId":"NCT00617903","phase":"PHASE2","title":"Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-01","conditions":"Papulopustular Rosacea","enrollment":83},{"nctId":"NCT01430312","phase":"PHASE1","title":"21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT01430533","phase":"PHASE1","title":"Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":240},{"nctId":"NCT01025635","phase":"PHASE2","title":"Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-12","conditions":"Papulopustular Rosacea","enrollment":401},{"nctId":"NCT03200912","phase":"PHASE3","title":"An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-08-19","conditions":"ACTINIC KERATOSIS","enrollment":507},{"nctId":"NCT03287791","phase":"PHASE3","title":"A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-07-19","conditions":"Rosacea","enrollment":924},{"nctId":"NCT03689010","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2017-12-12","conditions":"Rosacea","enrollment":1116},{"nctId":"NCT03441789","phase":"PHASE4","title":"Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"L.H. Kircik, M.D.","startDate":"2017-09-18","conditions":"Plaque Psoriasis","enrollment":28},{"nctId":"NCT02368210","phase":"PHASE3","title":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":151},{"nctId":"NCT02742441","phase":"PHASE3","title":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2016-06","conditions":"Plaque Psoriasis","enrollment":409},{"nctId":"NCT02367911","phase":"PHASE3","title":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":144},{"nctId":"NCT01323673","phase":"PHASE4","title":"Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-11-15","conditions":"Dermatitis, Chronic","enrollment":125},{"nctId":"NCT00842153","phase":"PHASE4","title":"Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2007-11","conditions":"Psoriasis","enrollment":58},{"nctId":"NCT01115322","phase":"PHASE1","title":"A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-04-01","conditions":"Acne Vulgaris","enrollment":38},{"nctId":"NCT01112787","phase":"PHASE1","title":"A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-03-26","conditions":"Acne Vulgaris","enrollment":39},{"nctId":"NCT01114841","phase":"PHASE1","title":"A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-03-31","conditions":"Acne Vulgaris","enrollment":254},{"nctId":"NCT01119651","phase":"PHASE1","title":"A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-06-14","conditions":"Acne Vulgaris","enrollment":59},{"nctId":"NCT01017120","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10-01","conditions":"Acne Vulgaris","enrollment":742},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT02601963","phase":"PHASE2","title":"Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2015-09","conditions":"Rosacea, Papulopustular Rosacea","enrollment":233},{"nctId":"NCT02173054","phase":"PHASE3","title":"An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2014-07","conditions":"Acne","enrollment":120},{"nctId":"NCT01139580","phase":"PHASE3","title":"The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-05","conditions":"Psoriasis","enrollment":363},{"nctId":"NCT01017146","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":744},{"nctId":"NCT00688519","phase":"PHASE3","title":"Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-03","conditions":"Psoriasis","enrollment":336},{"nctId":"NCT01745133","phase":"PHASE4","title":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Leon Kircik, M.D.","startDate":"2013-01","conditions":"Psoriasis","enrollment":63},{"nctId":"NCT00689481","phase":"PHASE3","title":"Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-03","conditions":"Psoriasis","enrollment":323},{"nctId":"NCT02658292","phase":"PHASE2","title":"Safety and Efficacy of NAFT900 in Children With Tinea Capitis","status":"WITHDRAWN","sponsor":"Merz North America, Inc.","startDate":"","conditions":"Tinea Capitis","enrollment":""},{"nctId":"NCT01226459","phase":"PHASE3","title":"Clinical Trial in Females for Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2010-09","conditions":"Androgenetic Alopecia","enrollment":404},{"nctId":"NCT01826461","phase":"PHASE2","title":"An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"PreCision Dermatology, Inc.","startDate":"2013-03","conditions":"Atopic Dermatitis","enrollment":151},{"nctId":"NCT01828177","phase":"PHASE2","title":"An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea","status":"UNKNOWN","sponsor":"PreCision Dermatology, Inc.","startDate":"2013-06","conditions":"Rosacea","enrollment":200},{"nctId":"NCT01319370","phase":"PHASE2","title":"Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia","status":"COMPLETED","sponsor":"Natalie GARCIA BARTELS","startDate":"2010-11","conditions":"Androgenetic Alopecia","enrollment":70},{"nctId":"NCT01353976","phase":"PHASE3","title":"Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis","status":"COMPLETED","sponsor":"AmDerma","startDate":"2011-05","conditions":"Tinea Pedis, Athlete's Foot","enrollment":264},{"nctId":"NCT00768599","phase":"PHASE2","title":"A Study of Econazole Foam 1% in Athlete's Foot","status":"COMPLETED","sponsor":"AmDerma","startDate":"2008-03","conditions":"Tinea Pedis, Athlete's Foot","enrollment":135},{"nctId":"NCT01696799","phase":"PHASE2","title":"Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years","status":"COMPLETED","sponsor":"AmDerma","startDate":"2011-09","conditions":"Interdigital Tinea Pedis","enrollment":42},{"nctId":"NCT01358240","phase":"PHASE3","title":"Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis","status":"COMPLETED","sponsor":"AmDerma","startDate":"2011-06","conditions":"Tinea Pedis, Athlete's Foot","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo","Vehicle","Quinnova Foam Vehicle","placebo"],"phase":"marketed","status":"active","brandName":"Vehicle Foam","genericName":"Vehicle Foam","companyName":"Vyne Therapeutics Inc.","companyId":"vyne-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Foam is a topical treatment used to study various skin conditions, including psoriasis, acne, and dermatitis, in clinical trials. It has been compared to other treatments such as Dermoval/Dermovate and Diprosone in a vasoconstriction trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":7},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}